Page last updated: 2024-12-06

tubulosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tubulosine is a natural product that has been isolated from the Chinese medicinal plant *Tripterygium wilfordii*. It exhibits a range of biological activities, including anti-inflammatory, immunosuppressive, and anti-cancer effects. Its complex structure, composed of a highly modified indole alkaloid scaffold, has stimulated significant interest in its synthetic and medicinal chemistry. The compound is known to inhibit the activity of several enzymes, including protein kinases and DNA topoisomerases. Research into tubulosine is ongoing, with a focus on developing its potential as a therapeutic agent for various diseases.'

tubulosine: indole derivative of main alkaloids of ipecac; RN given refers to cpd with unspecified isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tubulosine : A member of the class of beta-carbolines that is tubulosan bearing methoxy groups at positions 10 and 11 and a hydroxy group at the 8' position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID72341
CHEMBL ID518568
CHEBI ID9775
SCHEMBL ID1920742
MeSH IDM0054833

Synonyms (32)

Synonym
CHEBI:9775 ,
nsc-131547
1h-pyrido[3, 1-[[(2s,3r,11bs)-3-ethyl-1,3,4,6,7,11b-hexahydro- 9,10-dimethoxy-2h-benzo[a]quinolizin-2-yl]methyl]- 2,3,4,9-tetrahydro-, (1r)-
nsc131547 ,
tubulosan-8'-ol,11-dimethoxy-
10,11-dimethoxytubulosan-8'-ol
tubulosan-8'-ol, 10,11-dimethoxy-
1h-pyrido[3,4-b]indol-6-ol, 1-[[(2s,3r,11bs)-3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2h-benzo[a]quinolizin-2-yl]methyl]-2,3,4,9-tetrahydro-, (1r)-
(1r)-1-[[(2s,3r,11bs)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl]methyl]-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-6-ol
C09248
2632-29-3
tubulosine
(1r)-1-[[(2s,3r,11bs)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl]methyl]-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-6-ol
NCI131547
NCI60_000694
NCISTRUC2_001820
NCISTRUC1_001471
SR-02000000201-1
CHEMBL518568
unii-112a6z7sn5
nsc 131547
10,11-dimethoxytubulosanol
112a6z7sn5 ,
SCHEMBL1920742
1h-pyrido(3,4-b)indol-6-ol, 1-((3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2h-benzo(a)quinolizin-2-yl)methyl)-2,3,4,9-tetrahydro-, (2s-(2.alpha.(s*),3.beta.,11b.beta.))-
(1r)-1-(((2s,3r,11bs)-3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2h-benzo(a)quinolizin-2-yl)methyl)-2,3,4,9-tetrahydro-1h-pyrido(3,4-b)indol-6-ol
(-)-tubulosine
1h-pyrido(3,4-b)indol-6-ol, 1-(((2s,3r,11bs)-3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2h-benzo(a)quinolizin-2-yl)methyl)-2,3,4,9-tetrahydro-, (1r)-
bdbm50480281
Q27108491
(1r)-1-[[(2s,3r,11bs)-3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2h-benzo[a]quinolizin-2-yl]methyl]-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-6-ol
DTXSID701100319

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response experiments in primary cells confirmed pathway selectivity, but importantly also revealed differential inhibition of cell types and new druggability trends across multiple compounds."( High-content single-cell drug screening with phosphospecific flow cytometry.
Clutter, MR; Crane, JM; Krutzik, PO; Nolan, GP, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (6)

ClassDescription
isoquinoline alkaloidAny alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
beta-carbolinesAny pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID376034Cytotoxicity against human multidrug resistant KB cells in presence of vinblastine1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID336511Antitumor activity against Agrobacterium tumefaciens-induced crown gall tumors in potato by disk test
AID376038Cytotoxicity against human SK-N-SH cells1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID376030Cytotoxicity against human BC1 cells1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID336510Toxicity in brine shrimp
AID376028In vivo antitumor activity against mouse L1210 cells assessed as increase in life span at 2 mg/kg1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID376033Cytotoxicity against human KB cells1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID397122Inhibition of HIV1 RT
AID1616252Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Octahydro-Protoberberine and Protoemetine-Type Alkaloids from the Stems of
AID1616250Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Octahydro-Protoberberine and Protoemetine-Type Alkaloids from the Stems of
AID495065Inhibition of JAK-mediated interferon-gamma-induced Stat1 phosphorylation in human U937 cells by Phospho-Flow cytometry at 20 uM2008Nature chemical biology, Feb, Volume: 4, Issue:2
High-content single-cell drug screening with phosphospecific flow cytometry.
AID376031Cytotoxicity against human Lu1 cells1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID376035Cytotoxicity against human multidrug resistant KB cells in absence of vinblastine1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID336513Cytotoxicity against human 9KB cells
AID336517In vivo antitumor activity against mouse 3PS cells at 0.25 mg/kg, relative to control
AID376037Cytotoxicity against human SW626 cells1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID376032Cytotoxicity against human Col2 cells1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID336512Cytotoxicity against mouse 9PS cells
AID376036Cytotoxicity against human LNCAP cells1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID336515Cytotoxicity against human MCF7 cells
AID1616251Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Octahydro-Protoberberine and Protoemetine-Type Alkaloids from the Stems of
AID376039Cytotoxicity against mouse M109 cells1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID336514Cytotoxicity against human A549 cells
AID495066Inhibition of anisomycin-induced p38 phosphorylation in human U937 cells by Phospho-Flow cytometry at 20 uM2008Nature chemical biology, Feb, Volume: 4, Issue:2
High-content single-cell drug screening with phosphospecific flow cytometry.
AID376029In vivo antitumor activity against mouse P388 cells assessed as increase in life span at 2 mg/kg1999Journal of natural products, Sep, Volume: 62, Issue:9
1',2',3',4'-tetradehydrotubulosine, a cytotoxic alkaloid from Pogonopus speciosus.
AID495064Inhibition of JAK-mediated GM-CSF-induced Stat5 phosphorylation in human U937 cells by Phospho-Flow cytometry at 20 uM2008Nature chemical biology, Feb, Volume: 4, Issue:2
High-content single-cell drug screening with phosphospecific flow cytometry.
AID336516Cytotoxicity against human HT-29 cells
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (23.08)18.7374
1990's3 (23.08)18.2507
2000's4 (30.77)29.6817
2010's2 (15.38)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.67 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]